DIRAS3 enhances RNF19B-mediated RAC1 ubiquitination and degradation in non-small-cell lung cancer cells

Yingying Wang; Minli Wei; Min Su; Zhiyuan Du; Jiaxi Dong; Yu Zhang; Yingdi Wu; Xiaopeng Li; Ling Su; Xiangguo Liu

doi:10.1016/j.isci.2023.107157

DIRAS3 enhances RNF19B-mediated RAC1 ubiquitination and degradation in non-small-cell lung cancer cells

iScience. 2023 Jun 16;26(7):107157. doi: 10.1016/j.isci.2023.107157. eCollection 2023 Jul 21.

Authors

Yingying Wang¹, Minli Wei¹, Min Su¹, Zhiyuan Du¹, Jiaxi Dong¹, Yu Zhang¹, Yingdi Wu¹, Xiaopeng Li¹, Ling Su¹, Xiangguo Liu^{1

2}

Affiliations

¹ Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China.
² Key Laboratory of the Ministry of Education for Experimental Teratology, Shandong University, Jinan, China.

Abstract

Distant metastasis remains the leading cause of high mortality in patients with non-small-cell lung cancer (NSCLC). DIRAS3 is a candidate tumor suppressor protein that is decreased in various tumors. However, the regulatory mechanism of DIRAS3 on metastasis of NSCLC remains unclear. Here, we found that DIRAS3 suppressed the migration of NSCLC cells. Besides, DIRAS3 stimulated the polyubiquitination of RAC1 and suppressed its protein expression. Furthermore, RNF19B, a member of the RBR E3 ubiquitin ligase family, was observed to be the E3 ligase involved in the DIRAS3-induced polyubiquitination of RAC1. DIRAS3 could promote the binding of RAC1 and RNF19B, thus enhancing the degradation of RAC1 by the ubiquitin-proteasome pathway. Finally, the DIRAS3-RNF19B-RAC1 axis was confirmed to be associated with the malignant progression of NSCLC. These findings may be beneficial for developing potential prognostic markers of NSCLC and may provide an effective treatment strategy.

Keywords: Biotechnology; Cell biology; Molecular biology.